Unveiling the Complexities of Hereditary Angioedema

Area of Science:

• Genetics and immunology
• Rare disease research

Background:

• Hereditary angioedema (HAE) is a rare genetic disorder affecting 1 in 50,000–150,000 individuals globally.
• It manifests as recurrent, non-pruritic angioedema without urticaria.
• HAE is classified into three types based on C1 esterase inhibitor (C1-INH) levels and function.

Purpose of the Study:

• To review the pathophysiology, clinical presentations, and diagnostic challenges of HAE.
• To explore emerging biomarkers and innovative therapeutic strategies for HAE management and prevention.
• To emphasize the importance of family screening in HAE cases.

Main Methods:

• Literature review of HAE pathophysiology, clinical manifestations, diagnostics, and therapeutics.
• Analysis of current and emerging omics technologies for biomarker discovery.
• Synthesis of information on treatment advancements for acute management and long-term prevention.

Main Results:

• HAE types I, II, and III share similar clinical symptoms despite differing C1-INH mechanisms.
• Targeted therapies have revolutionized HAE management.
• Omics technologies offer potential for precise diagnostics and personalized treatment.

Conclusions:

• Understanding HAE pathophysiology has led to significant therapeutic breakthroughs.
• Biomarker discovery through omics technologies promises enhanced diagnostics and personalized medicine.
• Family screening is crucial for early detection and management of HAE.